MLN4924 alleviates autoimmune myocarditis by promoting Act1 degradation and blocking Act1-mediated mRNA stability
International Immunopharmacology · 2024-09 · 139 · 112716
DOI: 10.1016/j.intimp.2024.112716 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024-09. Verfasst von Zuli Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Key Laboratory of Henan province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. Hauptthemen laut MEDLINE: Myocarditis, Pyrimidines, Autoimmune Diseases, Adaptor Proteins, Signal Transducing. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Scientific Research Project of Colleges and Universities in Henan Province.
Abstract (Originalsprache)
BACKGROUND: Prolonged exposure to interleukin-17A (IL-17A) can induce autoimmune myocarditis, and MLN4924, an inhibitor of NEDD8 activating enzyme (NAE), has been reported to effectively suppress various inflammatory reactions. However, the effects of MLN4924 in IL-17A-mediated inflammation associated with autoimmune myocarditis remain uncertain. METHODS: An experimental autoimmune myocarditis (EAM) model was established and treated with MLN4924. The inflammation degree of heart tissues was assessed histopathologically. The expression levels of inflammatory cytokines and chemokines were measured using ELISA and RT-qPCR, respectively. Additionally, the interaction of biomacromolecules was detected through co-immunoprecipitation (Co-IP) and RNA immunoprecipitation (RIP). RESULTS: MLN4924 could attenuate IL-17A-induced inflammation. In the in vivo studies, MLN4924 treatment improved inflammatory responses, diminished immune cell infiltration and tissue fibrosis, and reduced the secretion of various inflammatory cytokines in serum, including IL-1β, IL-6, TNF-α, and MCP-1. In vitro experiments further corroborated these findings, showing that MLN4924 treatment reduced the secretion and transcription of pro-inflammatory factors, particularly MCP-1. Mechanistically, we confirmed that MLN4924 promoted Act1 ubiquitination degradation and disrupted Act1's interaction with IL-17R, thereby impeding the formation of the IL-17R/Act1/TRAF6 complex and subsequent activation of TAK1, c-Jun, and p65. Moreover, MLN4924 interfered with Act1's binding to mRNA, resulting in mRNA instability. CONCLUSIONS: In conclusion, MLN4924 effectively alleviated inflammatory symptoms in EAM by disrupting the interaction between IL and 17R and Act1, thereby reducing Act1-mediated mRNA stability and resulting in decreased expression of pro-inflammatory factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Key Laboratory of Henan province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
- Henan Engineering Research Center of Clinical Mass Spectrometry for Precision Medicine, Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
- Department of Clinical Laboratory, Key Laboratory of Henan province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. Electronic address: shenyan62687@126.com.
Förderung
- Key Scientific Research Project of Colleges and Universities in Henan Province
Zitieren
APA
Jiang, Z., Li, Z., Chen, Y., Nie, N., Liu, X., Liu, J., & Shen, Y. (2024). MLN4924 alleviates autoimmune myocarditis by promoting Act1 degradation and blocking Act1-mediated mRNA stability. International Immunopharmacology, 139, 112716. https://doi.org/10.1016/j.intimp.2024.112716
Vancouver
Jiang Z, Li Z, Chen Y, Nie N, Liu X, Liu J, et al. MLN4924 alleviates autoimmune myocarditis by promoting Act1 degradation and blocking Act1-mediated mRNA stability. International Immunopharmacology. 2024;139:112716. doi:10.1016/j.intimp.2024.112716
BibTeX
@article{Jiang2024,
author = {Jiang, Zuli and Li, Zhuolun and Chen, Youming and Nie, Na and Liu, Xiner and Liu, Jinlin and Shen, Yan},
title = {MLN4924 alleviates autoimmune myocarditis by promoting Act1 degradation and blocking Act1-mediated mRNA stability},
journal = {International Immunopharmacology},
year = {2024},
volume = {139},
pages = {112716},
doi = {10.1016/j.intimp.2024.112716}
}
EUVIMED